Ellagic acid encapsulated chitosan nanoparticles as anti-hemorrhagic agent.

Ellagic acid, a naturally occurring polyphenol was encapsulated in chitosan particles prepared by ionotropic gelation and characterized for its physicochemical properties. A maximum encapsulation efficiency of 49% was achieved. The blood clotting time and clot retraction time were calculated for different concentrations of ellagic acid, chitosan and ellagic acid-encapsulated chitosan. A reduction of 34% in the clot time and 16.4% in the retraction time was observed in ellagic acid-encapsulated chitosan when compared with free ellagic acid at concentrations as low as 0.1mg/mL. The physical blend in comparison to free ellagic acid displayed a reduction of 13.8% and 4.6% in the clotting time and retraction time respectively under similar conditions. This suggests that the encapsulation of ellagic acid favors thrombosis due to synergistic action of chitosan and ellagic acid on same molecular targets. This study demonstrates the potential of ellagic acid-chitosan system as an effective anti-hemorrhagic system.

[1]  G. Sharma,et al.  Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[2]  R. Muzzarelli.  Chitins and chitosans for the repair of wounded skin, nerve, cartilage and bone , 2009 .

[3]  P. Boonme,et al.  Nanoencapsulation of polyphenols for protective effect against colon-rectal cancer. , 2013, Biotechnology advances.

[4]  G. Müller‐Berghaus,et al.  Activation of Hageman factor by ellagic acid and the generalized Shwartzman reaction. , 1969, The American journal of pathology.

[5]  Michael V Sefton,et al.  Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. , 2004, Biomaterials.

[6]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[7]  A. Girolami,et al.  The effect of ellagic acid on coagulation in vivo. , 1966, Blood.

[8]  Z. Hussain,et al.  Chitosan nanoparticles as a percutaneous drug delivery system for hydrocortisone , 2012 .

[9]  L. Tocantins.  PLATELETS AND THE STRUCTURE AND PHYSICAL PROPERTIES OF BLOOD CLOTS , 1936 .

[10]  G. Galed,et al.  Temperature and pH-sensitive chitosan hydrogels: DSC, rheological and swelling evidence of a volume phase transition , 2007 .

[11]  Johan W M Heemskerk,et al.  Platelet Activation and Blood Coagulation , 2002, Thrombosis and Haemostasis.

[12]  S. Mirunalini,et al.  Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). , 2013, Colloids and surfaces. B, Biointerfaces.

[13]  M. Chopra,et al.  Synthesis, characterization, and evaluation of radical scavenging ability of ellagic acid-loaded nanogels , 2011 .

[14]  K. Koudouvo,et al.  Ethnopharmacological survey on antihemorrhagic medicinal plants in south of Benin. , 2013 .

[15]  Wei Wang,et al.  Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  R. Muzzarelli,et al.  Biochemistry, histology and clinical uses of chitins and chitosans in wound healing. , 1999, EXS.

[17]  R. Shuman,et al.  Chitosan: a new topical hemostatic agent for diffuse capillary bleeding in brain tissue. , 1984, Neurosurgery.

[18]  K. Preissner,et al.  Transforming Growth Factor-β1 Induces Expression of Human Coagulation Factor XII via Smad3 and JNK Signaling Pathways in Human Lung Fibroblasts* , 2010, The Journal of Biological Chemistry.

[19]  O. Tasaki,et al.  Impact on survival of whole-body computed tomography before emergency bleeding control in patients with severe blunt trauma , 2013, Critical Care.

[20]  S. Kelsey,et al.  Percutaneous Transluminal Coronary Angioplasty: Report of Complications from the National Heart, Lung, and Blood Institute PTCA Registry , 1983, Circulation.

[21]  M. Vijayakumar,et al.  Healing potential of Anogeissus latifolia for dermal wounds in rats. , 2004, Acta pharmaceutica.

[22]  K. R. Koerner,et al.  Review of hemostatic agents used in dentistry. , 2005, Dentistry today.

[23]  R. Muzzarelli,et al.  Chitosan stabilizes platelet growth factors and modulates stem cell differentiation toward tissue regeneration. , 2013, Carbohydrate polymers.

[24]  V. Jiménez‐Yuste,et al.  Management of bleeding disorders in adults , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  S. Nair,et al.  Biomaterials based on chitin and chitosan in wound dressing applications. , 2011, Biotechnology advances.

[26]  S. Moochhala,et al.  Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties. , 2008, Biomaterials.

[27]  Sungwoo Kim,et al.  Development of chitosan-ellagic acid films as a local drug delivery system to induce apoptotic death of human melanoma cells. , 2008, Journal of biomedical materials research. Part B, Applied biomaterials.

[28]  Cristóbal N. Aguilar,et al.  Ellagitannins: Biosynthesis, biodegradation and biological properties , 2011 .

[29]  Domenico Ribatti,et al.  Giulio Bizzozero and the discovery of platelets. , 2007, Leukemia research.

[30]  Hui Xu,et al.  Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. , 2002, International journal of pharmaceutics.

[31]  Peter Rhee,et al.  Hemorrhage control in the battlefield: role of new hemostatic agents. , 2005, Military medicine.

[32]  Suay Ozmen,et al.  Is local ointment or cauterization more effective in childhood recurrent epistaxis. , 2012, International Journal of Pediatric Otorhinolaryngology.

[33]  A. Adam,et al.  Studies on the vascular and hematological changes induced by ellagic acid in rats , 1987, Agents and Actions.

[34]  J. Mustard,et al.  Platelet interaction with polymerizing fibrin. , 1972, The Journal of clinical investigation.

[35]  Y. Okamoto,et al.  Chitin and chitosan activate complement via the alternative pathway , 1998 .

[36]  Cristóbal N. Aguilar,et al.  Euphorbia antisyphilitica residues as a new source of ellagic acid , 2010 .

[37]  Kwok-Fai So,et al.  Nano hemostat solution: immediate hemostasis at the nanoscale. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[38]  M. Levi,et al.  Management of bleeding disorders by prohemostatic therapy , 2002, International journal of hematology.

[39]  P. White,et al.  A CLINICAL STUDY OF THE COAGULATION TIME OF BLOOD , 1913 .

[40]  M. Peter.  Applications and Environmental Aspects of Chitin and Chitosan , 1995 .

[41]  M. Dobrovolskaia,et al.  Method for in vitro analysis of nanoparticle thrombogenic properties. , 2011, Methods in molecular biology.

[42]  B. Cooper,et al.  Mechanisms of disease: A textbook of comparative general pathology , 2001 .

[43]  Hsiao-Pei Tu,et al.  Releasing growth factors from activated human platelets after chitosan stimulation: a possible bio-material for platelet-rich plasma preparation. , 2006, Clinical oral implants research.

[44]  U. Muller-eberhard,et al.  Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin. , 1985, The Journal of clinical investigation.

[45]  J. Vournakis,et al.  Isolation, purification, and characterization of poly-N-acetyl glucosamine use as a hemostatic agent. , 2004, The Journal of trauma.

[46]  Janice A. Zawaski,et al.  The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial. , 2009, Biomaterials.

[47]  O. Ratnoff.  Studies on the inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments. , 1981, Blood.